Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease
US9700531B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 19, 2015 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Mar 19, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.